FABRAZYME35mg

FABRAZYME (Agalsidase Beta) 35mg by Genzyme (Sanofi) is the gold-standard enzyme replacement therapy (ERT) for Fabry disease, a rare X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A enzyme. Fabry disease affects approximately 1 in 40,000-60,000 males and leads to progressive accumulation of globotriaosylceramide (GL-3/Gb3) in lysosomes throughout the body. Without treatment, patients develop progressive renal failure, hypertrophic cardiomyopathy, stroke, and severe neuropathic pain. Fabrazyme provides recombinant human alpha-galactosidase A produced in Chinese Hamster Ovary (CHO) cells. The enzyme is taken up by cells via mannose-6-phosphate receptors, transported to lysosomes, and catalyzes hydrolysis of accumulated GL-3. FDA-approved since 2003, Fabrazyme has demonstrated sustained stabilization of renal function and reduction of cardiac mass over 10+ years of treatment. As a licensed pharmaceutical supplier, we provide authentic Genzyme/Sanofi Fabrazyme with validated cold chain handling, certificate of authenticity, and competitive wholesale pricing for hospitals and metabolic disease centers worldwide.